Ailomics Therapeutics utilizes patient-derived omics data and AI-augmented bioinformatics to identify novel therapeutic targets for immune diseases and tumors. The company develops first-in-class drug candidates and companion diagnostics to address significant unmet medical needs in patient stratification and treatment efficacy.
Funding
$8.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCTIFounders
Product
Problem
Many immune diseases and tumors lack effective treatments due to incomplete understanding of their underlying biological mechanisms and a lack of suitable drug targets. Current drug development approaches often fail to translate from preclinical models to clinical success, resulting in high failure rates and unmet medical needs.
Solution
Ailomics Therapeutics is developing first-in-class therapeutics for immune diseases and tumors by leveraging patient-derived omics data and AI-augmented bioinformatics. The company's approach involves analyzing patient samples to identify novel therapeutic targets and then developing human disease models to validate these targets and screen for functional molecules. Ailomics also focuses on discovering predictive biomarkers and developing companion diagnostics for patient stratification in clinical trials, aiming to improve treatment efficacy and patient outcomes. The company's R&D model starts from patient data, identifies novel targets, develops human disease models, discovers drug candidates, and then tests them back on patient samples.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel drug candidates and companion diagnostics, as well as patients suffering from immune diseases and tumors with limited treatment options.
Features
- Utilizes patient-derived omics data (genomics, proteomics, etc.) to understand disease biology.
- Employs AI-augmented bioinformatics analytics to identify novel drug targets.
- Develops high-translatability human disease models for target validation and drug screening.
- Focuses on first-in-class drug candidates for diseases with significant unmet medical needs.
- Develops companion diagnostics for patient stratification and prediction of treatment response.